KLCM Advisors Inc. acquired a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 74,083 shares of the medical equipment provider's stock, valued at approximately $7,825,000.
A number of other large investors have also recently made changes to their positions in ZBH. Roman Butler Fullerton & Co. purchased a new position in shares of Zimmer Biomet in the 4th quarter valued at approximately $473,000. Geode Capital Management LLC lifted its stake in shares of Zimmer Biomet by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider's stock valued at $524,942,000 after purchasing an additional 125,852 shares during the period. M&T Bank Corp lifted its stake in shares of Zimmer Biomet by 48.4% in the 3rd quarter. M&T Bank Corp now owns 26,719 shares of the medical equipment provider's stock valued at $2,884,000 after purchasing an additional 8,709 shares during the period. Peddock Capital Advisors LLC purchased a new position in shares of Zimmer Biomet in the 4th quarter valued at approximately $654,000. Finally, National Pension Service lifted its stake in shares of Zimmer Biomet by 3.8% in the 3rd quarter. National Pension Service now owns 369,547 shares of the medical equipment provider's stock valued at $39,893,000 after purchasing an additional 13,612 shares during the period. 88.89% of the stock is currently owned by institutional investors.
Zimmer Biomet Price Performance
Shares of NYSE ZBH traded up $0.98 during mid-day trading on Wednesday, reaching $103.16. The company's stock had a trading volume of 912,139 shares, compared to its average volume of 1,873,339. The firm has a market capitalization of $20.54 billion, a PE ratio of 23.13, a P/E/G ratio of 1.89 and a beta of 1.02. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. The stock has a fifty day moving average of $106.04 and a two-hundred day moving average of $107.54. Zimmer Biomet Holdings, Inc. has a 52 week low of $97.69 and a 52 week high of $133.90.
Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, topping analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period last year, the business earned $2.20 earnings per share. As a group, sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.
Zimmer Biomet Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Monday, December 30th were given a $0.24 dividend. The ex-dividend date of this dividend was Monday, December 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.93%. Zimmer Biomet's dividend payout ratio is currently 21.57%.
Analyst Upgrades and Downgrades
A number of research analysts have issued reports on ZBH shares. Barclays lowered their price objective on Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating for the company in a research note on Monday, February 10th. JPMorgan Chase & Co. upgraded Zimmer Biomet from a "neutral" rating to an "overweight" rating and lifted their price objective for the company from $125.00 to $128.00 in a research note on Tuesday, December 17th. Needham & Company LLC reiterated a "hold" rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Royal Bank of Canada lowered their price objective on Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating for the company in a research note on Friday, February 7th. Finally, JMP Securities restated a "market outperform" rating and issued a $140.00 price target on shares of Zimmer Biomet in a research note on Friday, February 7th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have given a buy rating to the company's stock. Based on data from MarketBeat, Zimmer Biomet currently has a consensus rating of "Hold" and an average target price of $124.15.
Check Out Our Latest Stock Analysis on ZBH
About Zimmer Biomet
(
Free Report)
Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.
See Also
Before you consider Zimmer Biomet, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zimmer Biomet wasn't on the list.
While Zimmer Biomet currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
